FDA Delegation Visits SMS to Discuss and Explore Collaborative Opportunities for Industry Advancement

On January 27, 2025, SMS Corporation had the honor of hosting a delegation from the Health Product Economics Division of the Food and Drug Administration (FDA).

The session serves as a valuable platform for sharing experiences, discussing common challenges, and exploring potential opportunities for future collaboration that could enhance the Thai pharmaceutical and cosmetic industries.

Dr. Werawat Lertwanawatana, CEO of SMS Corporation, warmly welcomes a delegation from the Food and Drug Administration (FDA), led by Sitanun Poonpolsub, Director of the International Affairs Division, and including esteemed representatives including pharmacist practitioners. Following his welcoming address, the SMS team provided an overview of the company, highlighting its mission and significant contributions to the cassava industry.

The event features insightful presentations by SMS specialists. Dr. Waesarat Soontornchaiboon, Product Innovation Manager, showcased the functional benefits of DAVAMED™ C1, a high-performance compressible starch specifically designed for pharmaceutical tablet excipients.

Additionally, Dr. Suchitra Wongprayoon, Senior Researcher of Product Development, presents innovative applications of starch as a viable alternative to gelatin in soft capsules and supplement gummies, underscoring SMS's commitment to advancing health and wellness solutions.

The day concludes with productive discussions between the FDA team and SMS representatives, exploring potential avenues for future collaboration.This visit marks a significant milestone in strengthening public-private partnerships to develop innovative health-economic products that benefit society and enhance Thai pharmaceutical and cosmetic industries.